Ultragenyx's Dojolvi (UX007/triheptanoin) Receives the US FDA's Approval to Treat Long-Chain Fatty Acid Oxidation Disorders
Shots:
- Ultragenyx is a highly purified- pharmaceutical-grade- odd-carbon medium-chain triglyceride consisting of three 7-carbon fatty acids on a glycerol backbone created via a multi-step chemical process
- The FDA approved Dojolvi as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD)
- The company expects its availability in the next 30 days while for its access the Ultragenyx’s UltraCare program will help patients and caregivers to understand insurance coverage and assist them in finding financial support for Ultragenyx medicines
Ref: Ultragenyx | Image: Behance
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com